# US 2026/0102420 A1 · Cancer immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0102420 A1
- Document ID: US20260102420A1
- Status: Published application
- Kind: A1
- Application number: 19/215,007
- Filed: 2025-05-21
- Published: 2026-04-16
- Earliest claimed: 2022-11-29
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Stephan Gasser; Katrin Groebke Zbinden; Claudio Murgia; Tobias Schmidt; Antonio Sorrentino; Pablo Umaña
- Web page: https://patentgrep.com/patent/US20260102420A1

## CPC

- A61K 31/7028: Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K 31/7024: Esters of saccharides
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/33: Antibodies; T-cell engagers
- A61K 40/4266: {Carcinoembryonic antigen [CEA]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- A61K 2239/51: Stomach
- A61K 2239/57: Skin; melanoma
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to combination therapies employing T cell activation and UAP1 inhibitors, and the use of these combination therapies for the treatment of cancer.

## Claims

### Claim 1

(canceled)

### Claim 2

A method for treatment of cancer in an individual,
wherein said method comprises:
(a) administration of a therapeutically effective dose of UDP-N-acetylhexosamine pyrophosphorylase (UAP1) inhibitor to the individual, and
(b) administration of a therapeutically effective dose of an immunotherapy to the individual.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 2)

The method of claim 2, wherein the immunotherapy comprises adoptive cell transfer, administration of monoclonal antibodies, administration of cytokines, administration of a cancer vaccine, T cell engaging therapies, administration of PD-1 axis binding antagonists or any combination thereof.

### Claim 6 (depends on 2)

The method of claim 2, wherein administration of the UAP1 inhibitor causes
(i) an increase of the activity of the immunotherapy,
(ii) an increase of the activation of T cells induced by the immunotherapy,
(iii) an increase of the proliferation of T cells induced by the immunotherapy,
(iv) an increase of the cytotoxic activity of T cells induced by the immunotherapy,
(v) an increase of T cell receptor signaling in T cells induced by the immunotherapy,
(vi) an increase of early activation markers CD25 and/or CD69 in T cells (induced by the immunotherapy),
(vii) an increase of cytokine secretion by T cells induced by the immunotherapy, wherein said cytokine is one or more of IL-2, TNF-α, and/or IFN-γ; and/or
(viii) an increase of cytolytic effector molecule secretion by T cells induced by the immunotherapy, particularly wherein the cytolytic effector molecule is granzyme-B or perforin;
wherein said T cells are CD8+ T cells or CD4+ cells.

### Claim 7 (depends on 6)

The method of claim 6, wherein administration of the UAP1 inhibitor causes increase of the level of one of more cytokine in the individual, wherein said one or more cytokine is IL-2, TNF-α, and/or IFN-γ.

### Claim 8 (depends on 2)

The method of claim 2, wherein administration of the UAP1 inhibitor is (i) before, concurrent to, or after the administration of the immunotherapy, (ii) intermittently or continuously, and/or (iii) oral.

### Claim at position 9

9-12. (canceled)

### Claim 13 (depends on 2)

The method of claim 2, wherein administration of the UAP1 inhibitor is associated with the first administration of the immunotherapy.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 2)

The method of claim 2, wherein the immunotherapy is a T cell bispecific antibody, wherein the T cell bispecific antibody comprises an antigen binding moiety that binds to CD3 and an antigen binding moiety that binds to a target cell antigen.

### Claim 17

(canceled)

### Claim 18 (depends on 16)

The method of claim 16, wherein the target cell antigen is carcinoembryonic antigen (CEA); and wherein the cancer is a carcinoembryonic antigen (CEA)-expressing cancer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the T cell bispecific antibody comprises:
(i) a first antigen binding moiety that binds to CD3 and comprises a heavy chain variable region comprising the heavy chain CDR (HCDR) 1 of SEQ ID NO: 9, the HCDR2 of SEQ ID NO: 11, and the HCDR3 of SEQ ID NO: 12; and a light chain variable region comprising the light chain CDR (LCDR) 1 of SEQ ID NO: 16, the LCDR2 of SEQ ID NO: 17 and the LCDR3 of SEQ ID NO: 18; and
(ii) a second antigen binding moiety that binds to CEA and comprises a heavy chain variable region comprising the heavy chain CDR (HCDR) 1 of SEQ ID NO: 36, the HCDR2 of SEQ ID NO: 37, and the HCDR3 of SEQ ID NO: 38; and a light chain variable region comprising the light chain CDR (LCDR) 1 of SEQ ID NO: 39, the LCDR2 of SEQ ID NO: 40 and the LCDR3 of SEQ ID NO: 41.

### Claim 20 (depends on 18)

The method of claim 18, wherein the T cell bispecific antibody comprises a third antigen binding moiety that binds to CEA and/or an Fc domain composed of a first and a second subunit.

### Claim 21 (depends on 18)

The method of claim 18, wherein the T cell bispecific antibody comprises;
(i) a first antigen binding moiety that binds to CD3, comprising a heavy chain variable region comprising the heavy chain CDR (HCDR) 1 of SEQ ID NO: 9, the HCDR2 of SEQ ID NO: 11, and the HCDR3 of SEQ ID NO: 12; and a light chain variable region comprising the light chain CDR (LCDR) 1 of SEQ ID NO: 16, the LCDR2 of SEQ ID NO: 17 and the LCDR3 of SEQ ID NO: 18, wherein the first antigen binding moiety is a crossover Fab molecule wherein either the variable or the constant regions of the Fab light chain and the Fab heavy chain are exchanged;
(ii) a second and a third antigen binding moiety that bind to CEA, comprising a heavy chain variable region comprising the heavy chain CDR (HCDR) 1 of SEQ ID NO: 36, the HCDR2 of SEQ ID NO: 37, and the HCDR3 of SEQ ID NO: 38; and a light chain variable region comprising the light chain CDR (LCDR) 1 of SEQ ID NO: 39, the LCDR2 of SEQ ID NO: 40 and the LCDR3 of SEQ ID NO: 41; wherein the second and third antigen binding moiety are each a Fab molecule, particularly a conventional Fab molecule;
(iii) an Fc domain composed of a first and a second subunit,
wherein the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety, and the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, and wherein the third antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain.

### Claim 22 (depends on 19)

The method of claim 19, wherein the first antigen binding moiety of the T cell bispecific antibody comprises a heavy chain variable region sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 14 and a light chain variable region sequence that is at least identical to the amino acid sequence of SEQ ID NO: 19, and/or the second and (where present) third antigen binding moiety of the T cell bispecific antibody comprise a heavy chain variable region sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 14 and a light chain variable region sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 19.

### Claim 23

(canceled)

### Claim 24 (depends on 2)

The method of claim 2, wherein the immunotherapy is cibisatamab.

### Claim 25 (depends on 16)

The method of claim 16, wherein the target cell antigen is epithelial cellular adhesion molecule (EpCAM); and wherein the cancer is an epithelial cellular adhesion molecule (EpCAM)-expressing cancer.

### Claim 26 (depends on 25)

The method of claim 25, wherein the T cell bispecific antibody comprises:
(i) a first antigen binding moiety that binds to CD3 and comprises a heavy chain variable region comprising the heavy chain CDR (HCDR) 1 of SEQ ID NO: 9, the HCDR2 of SEQ ID NO: 11, and the HCDR3 of SEQ ID NO: 12; and a light chain variable region comprising the light chain CDR (LCDR) 1 of SEQ ID NO: 16, the LCDR2 of SEQ ID NO: 17 and the LCDR3 of SEQ ID NO: 18; and
(ii) a second antigen binding moiety that binds to EpCAM and comprises a heavy chain variable region comprising the heavy chain CDR (HCDR) 1 of SEQ ID NO: 60, the HCDR2 of SEQ ID NO: 61, and the HCDR3 of SEQ ID NO: 62; and a light chain variable region comprising the light chain CDR (LCDR) 1 of SEQ ID NO: 63, the LCDR2 of SEQ ID NO: 64 and the LCDR3 of SEQ ID NO: 65.

### Claim 27 (depends on 26)

The method of claim 26, wherein the T cell bispecific antibody comprises a third antigen binding moiety that binds to EpCAM and/or an Fc domain composed of a first and a second subunit.

### Claim 28

(canceled)

### Claim 29 (depends on 26)

The method of claim 26, wherein the first antigen binding moiety of the T cell bispecific antibody comprises a heavy chain variable region sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 14 and a light chain variable region sequence that is at least identical to the amino acid sequence of SEQ ID NO: 19, and/or the second and (where present) third antigen binding moiety of the T cell bispecific antibody comprise a heavy chain variable region sequence that is at least identical to the amino acid sequence of SEQ ID NO: 66 and a light chain variable region sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 67.

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 16)

The method of claim 16, wherein the target cell antigen is tyrosine-related protein 1 (TYRP1); and wherein the cancer is a tyrosine-related protein 1 (TYRP1)-expressing cancer.

### Claim 33 (depends on 32)

The method of claim 32, wherein the T cell bispecific antibody comprises:
(i) a first antigen binding moiety that binds to CD3 and comprises a heavy chain variable region comprising the heavy chain CDR (HCDR) 1 of SEQ ID NO: 10, the HCDR2 of SEQ ID NO: 11, and the HCDR3 of SEQ ID NO: 13; and a light chain variable region comprising the light chain CDR (LCDR) 1 of SEQ ID NO: 16, the LCDR2 of SEQ ID NO: 17 and the LCDR3 of SEQ ID NO: 18; and
(ii) a second antigen binding moiety that binds to TYRP1 and comprises a heavy chain variable region comprising the heavy chain CDR (HCDR) 1 of SEQ ID NO: 23, the HCDR2 of SEQ ID NO: 24, and the HCDR3 of SEQ ID NO: 25; and a light chain variable region comprising the light chain CDR (LCDR) 1 of SEQ ID NO: 27, the LCDR2 of SEQ ID NO: 28 and the LCDR3 of SEQ ID NO: 29.

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36 (depends on 33)

The method of claim 33, wherein the first antigen binding moiety of the T cell bispecific antibody comprises a heavy chain variable region sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 15 and a light chain variable region sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 19, and/or the second and (where present) third antigen binding moiety of the T cell bispecific antibody comprise a heavy chain variable region sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 26 and a light chain variable region sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 30.

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39 (depends on 16)

The method of claim 16, wherein the target cell antigen is a peptide presented on a MHC class I molecule.

### Claim 40 (depends on 2)

The method of claim 2, wherein the immunotherapy is a PD-1 axis binding antagonist.

### Claim 41 (depends on 40)

The method of claim 40, wherein the PD-1 axis binding antagonist is selected from the group consisting of a PD-1 binding antagonist, a PDL1 binding antagonist and a PDL2 binding antagonist.

### Claim 42

(canceled)

### Claim 43 (depends on 41)

The method of claim 41, wherein the immunotherapy is ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, or avelumab.

### Claim at position 41

44-46. (canceled)

### Claim 47 (depends on 2)

The method of claim 2, wherein the immunotherapy comprises administering chimeric antigen receptor expressing T-cells (CAR T-cells), T-cell receptor (TCR) modified T-cells, tumor-infiltrating lymphocytes (TIL), chimeric antigen receptor (CAR)-modified natural killer cells, T cell receptor (TCR) transduced cells, or dendritic cells, or any combination thereof.

### Claim 48 (depends on 2)

The method of claim 2, wherein the immunotherapy comprises administration of a cancer vaccine.

### Claim 49 (depends on 18)

The method of claim 18, wherein the cancer is
colorectal cancer, lung cancer, pancreatic cancer, breast cancer, or gastric cancer.

### Claim 50 (depends on 25)

The method of claim 25, wherein the cancer is
colorectal, breast, gastric, prostate, ovarian, or lung cancer.

### Claim 51 (depends on 32)

The method of claim 32, wherein the cancer is
melanoma.

### Claim 52

(canceled)
